Skip to main content
MTLS
NASDAQ Technology

Materialise Files Full Q3 2026 Statements: Net Profit Falls to €1.4M, Adjusted EBIT Margin 3.7%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Software Stocks · Technology
Sentiment info
Negative
Importance info
7
Price
$7.7
Mkt Cap
$400.476M
52W Low
$4.78
52W High
$8.82
52W Position info
61% above low
Off High info
13% below high
Rel. Volume info
6.9× avg
Market data snapshot near publication time

MTLS sits 61% above its 52-week low of $4.78 on elevated volume (6.9× avg).

Summary

Materialise filed the full Q3 2026 financials behind yesterday's miss: revenue up 2.1% to €67.7M but operating profit down to €1.3M from €2.5M as costs rose 7.8%. Cash stands at €153.5M with a €82.5M net cash position.


Key Events · Earnings and Guidance · MTLS

  • Q3 Revenue Grows 2.1%, Profit Falls

    Revenue rose to €67,670k from €66,259k, but operating profit dropped to €1,343k from €2,522k and net profit to €1,383k from €1,848k.

  • Cost Growth Squeezes Margins

    R&D, S&M and G&A rose 7.8% in aggregate to €38,830k, driven by 11.9% higher R&D; Adjusted EBIT margin fell to 3.7% from 4.4% and Adjusted EBITDA to €8,046k from €8,428k.

  • Medical Offsets Software and Manufacturing

    Medical revenue grew 9.7% to €36,542k at a 27.4% segment EBITDA margin, while Software fell to €9,864k from €10,286k and Manufacturing to €21,266k from €22,677k.

  • Net Cash Position Rises to €82.5M

    Cash reached €153,529k versus €133,918k at December 31, 2025, and net cash rose by €11,668k to €82,473k despite gross debt increasing to €71,056k.


Analysis · MTLS · Technology

Yesterday's headline already delivered the shock — a Q3 miss that knocked the stock down about 22% — so this 6-K is the detailed accounting behind it, not a fresh surprise. What it confirms is a margin squeeze rather than a revenue collapse: revenue rose 2.1% to €67.7M and gross margin actually improved to 57.7%, but operating expenses grew 7.8% (R&D up 11.9%), cutting operating profit to €1.3M from €2.5M and Adjusted EBIT to €2.5M from €2.9M. Medical carried the quarter (+9.7% revenue, 27.4% segment EBITDA margin) while Software and Manufacturing both shrank year over year. The balance sheet is the offset: cash of €153.5M and a net cash position of €82.5M, so there is no funding pressure behind the earnings miss.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTLS was trading at $7.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $400.5M. The 52-week trading range was $4.78 to $8.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTLS - Latest Insights

MTLS
Oct 28, 2026, 10:45 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $6.76
Real-time Price: $6.59 info
Change: -$0.165 (-2%) info
Market Cap: $413.175M info
MTLS
Aug 27, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $6.59 info
Change: -$0.780 (-11%) info
Market Cap: $413.175M info
MTLS
Aug 27, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $6.80
Real-time Price: $6.59 info
Change: -$0.210 (-3%) info
Market Cap: $413.175M info
MTLS
Jul 06, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.32
Real-time Price: $6.59 info
Change: -$0.730 (-10%) info
Market Cap: $413.175M info
MTLS
Jun 29, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.16
Real-time Price: $6.59 info
Change: -$0.570 (-8%) info
Market Cap: $413.175M info